Empowered Funds LLC Boosts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Empowered Funds LLC raised its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 6.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 49,267 shares of the biopharmaceutical company’s stock after buying an additional 2,836 shares during the period. Empowered Funds LLC’s holdings in TG Therapeutics were worth $1,483,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TGTX. Creative Planning boosted its position in TG Therapeutics by 19.2% in the 3rd quarter. Creative Planning now owns 55,832 shares of the biopharmaceutical company’s stock valued at $1,306,000 after buying an additional 8,993 shares during the period. NBC Securities Inc. boosted its position in TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 485 shares during the period. Vontobel Holding Ltd. purchased a new position in TG Therapeutics in the 3rd quarter valued at approximately $222,000. Blue Trust Inc. boosted its position in TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 849 shares during the period. Finally, Raymond James & Associates boosted its position in TG Therapeutics by 35.9% in the 3rd quarter. Raymond James & Associates now owns 170,160 shares of the biopharmaceutical company’s stock valued at $3,980,000 after buying an additional 44,972 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Analyst Ratings Changes

TGTX has been the subject of several recent research reports. The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. TD Cowen began coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective on the stock. StockNews.com lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 31st. JPMorgan Chase & Co. raised their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. Finally, HC Wainwright restated a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX opened at $30.71 on Friday. The company’s fifty day moving average price is $31.15 and its 200 day moving average price is $27.36. TG Therapeutics, Inc. has a 12 month low of $12.84 and a 12 month high of $36.84. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a market capitalization of $4.78 billion, a P/E ratio of -307.07 and a beta of 2.26.

Insider Buying and Selling at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.50% of the stock is currently owned by company insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.